Alembic – Recall of telmisartan

- On March 24, 2021, Alembic announced a voluntary, consumer-level recall of one lot of telmisartan 20 mg tablets because of a market complaint received which stated that one bottle labeled as 30-count telmisartan 20 mg tablets, incorrectly contained 30 tablets of telmisartan 40 mg tablets.
- The recalled lot is listed below:

Product Description	NDC#	Lot# (Expiration Date)
Telmisartan 20 mg tablets, 30-count bottle	62332-087-30	1905005661 (3/2022)

- Telmisartan is indicated for the treatment of hypertension.
- Patients who inadvertently take telmisartan 40 mg tablets instead of their prescribed 20 mg tablets for a prolonged period of time, could experience low blood pressure, worsening of kidney function, or an elevation of potassium which can be life-threatening.
- To date, Alembic has not received any reports of adverse events related to this recall.
- The wrong product can be identified by checking the shape and embossing details on the tablets.
    - Thirty count bottles of telmisartan 20 mg tablets made by Alembic may incorrectly contain oval shaped white to off-white tablets debossed with L203 on one side instead of the correct product - round shaped white to off-white tablets debossed with L 202 on one side.
- Patients that may have the recalled telmisartan 20 mg tablets should continue taking their medication and discuss their therapy with a pharmacist or healthcare provider until a replacement is obtained.
- Patients should contact their physician or healthcare provider if they have experienced any problems that may be related to the recalled telmisartan.
- Anyone with an existing inventory of the recalled product should stop use, distribution and quarantine the product immediately.
- Contact Alembic by phone at **1-908-552-5839** or by email at **david.cobb@alembicusa.com** for more information about this recall.